Health Literacy and Clinical Trial Participation in French Cancer Patients: A National Survey

Abstract

Few studies have explored the relationship between health literacy (HL) and trial participation. In this context, we aimed to study this relationship in French cancer patients. We used data from the French national VIe après le CANcer (VICAN) survey. Two questionnaire items focused on previous invitations to participate in clinical trials and subsequent enrollment. The Single Item Literacy Screener was used to measure functional HL. In total, 1954 cancer patients responded to both VICAN surveys (two and five years after diagnosis). Mean age was 54.1 ± 12.7 years at diagnosis, and 37.6% were classified as having limited HL. One in ten (10.3%) respondents reported having been previously invited to participate in a clinical trial. Of these, 75.5% had enrolled. Limited HL was associated with fewer trial invitations but not with enrollment once invited. Multivariate analysis confirmed the negative effect of limited HL on clinical trial invitation (adjOR = 0.55 (0.39 to 0.77), p < 0.001) after adjustment for multiple characteristics. Patients with limited HL received fewer invitations to participate in trials but were likely to enroll when asked. Addressing HL is necessary to create a more inclusive health system and to reduce inequalities not only in access to innovative cancer care, but to health inequalities in general.

The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex

“…In our center 7.8% of the ICI treatments were applied in the context of clinical trials. This is very similar to the contemporary clinical trial participation rates of 7.7–8.1% in the US (Unger et al 2019 ; Byrne et al 2014 ) and 7.7% in France (Ousseine 2022 ). Importantly, advanced age did not seem to be a limitation for ICI prescription, since 27.8% of the patients were > 75 years at time of treatment prescription.…”

The mediating effect of shared decision-making in enhancing patient satisfaction with participation in cancer clinical trials

“…Thus, when study team members approach or recommend patients for clinical trials, the informed consent process should consider the patients’ education levels. As noted in previous studies, 37 , 38 patients with limited health literacy (HL) might have fewer opportunities to participate in clinical trials. Those studies suggest that the low HL might have a negative effect or impact on being comprehensive in understanding the informed consent form.…”

Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach

“…Moreover, it is known that very few patients will turn down an invitation to participate in a cancer CT [ 9 ]. This implies that further targeting on the individual level (such as increasing the provision of consent or estimating consent as a function of the personality type [ 24 ]) is misguided. Our results also raise the issue of the impact of national health insurance schemes on inclusion.…”